文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

停用与继续ACEI/ARB对COVID-19住院患者30天内出院存活天数的影响:一项随机临床试验

Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2021-01-01
一句话结论轻中度COVID-19住院且入院前在用ACEI/ARB者,停用与继续用药30天出院存活天数无显著差异,不常规建议停用。

该随机临床试验纳入巴西659例住院的轻中度COVID-19患者,入院前均在使用ACEI或ARB,随机分为停药组(n=334)与继续用药组(n=325)。主要终点为30天内出院存活天数,停药组均值21.9天(SD 8)vs 继续组22.9天(SD 7.1),均值比0.95(95%CI 0.90-1.01),无显著差异。死亡、心血管死亡及COVID-19进展等次要终点亦无统计学显著差异。结论不支持对轻中度COVID-19住院且有治疗指征者常规停用ACEI/ARB。

要点

  • 轻中度COVID-19住院且入院前在用ACEI/ARB者,停药与继续用药30天出院存活天数均值比0.95(95%CI 0.90-1.01),无显著差异。
  • 死亡:停药组2.7% vs 继续组2.8%(OR 0.97,95%CI 0.38-2.52),无统计学显著差异。
  • COVID-19进展:停药组38.3% vs 继续组32.3%(OR 1.30,95%CI 0.95-1.80),无统计学显著差异。
  • 最常见不良事件为需有创机械通气的呼吸衰竭(停药9.6% vs 继续7.7%)与需血管升压药的休克(8.4% vs 7.1%)。
  • 有ACEI/ARB治疗指征的轻中度COVID-19住院患者,不因COVID-19诊断而常规停药。

适用人群与场景

  • 巴西住院的轻中度COVID-19患者,入院前已在使用ACEI或ARB(n=659,100%完成试验)。
  • 中位年龄55.1岁(IQR 46.1-65.0),14.7%为70岁及以上,40.4%为女性。
  • 基线27.2%患者室内空气下血氧饱和度低于94%;入院时57.1%为轻度、42.9%为中度。
  • 症状出现至入院中位时间6天(IQR 4-9天)。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 第一步:确认患者入院前在用ACEI或ARB且为轻中度COVID-19住院。
  • 第二步:评估是否存在ACEI/ARB治疗指征;原文结论为有指征者不因COVID-19常规停药。
  • 第三步:原文未给出具体药物剂量、给药途径、频次或目标值。

红旗征与不能漏的情况

  • 需有创机械通气的呼吸衰竭(停药组9.6% vs 继续组7.7%)。
  • 需血管升压药的休克(停药组8.4% vs 继续组7.1%)。
  • 急性心肌梗死(停药组7.5% vs 继续组4.6%)。
  • 新发或加重的心力衰竭(停药组4.2% vs 继续组4.9%)。
  • 需血液透析的急性肾衰竭(停药组3.3% vs 继续组2.8%)。

研究设计与关键结果

  • 研究类型:随机临床试验,单国(巴西)多中心,659例,停药组334例 vs 继续组325例。
  • 主要终点30天出院存活天数:停药组均值21.9天(SD 8)vs 继续组22.9天(SD 7.1),均值比0.95(95%CI 0.90-1.01),无显著差异。
  • 死亡:2.7% vs 2.8%,OR 0.97(95%CI 0.38-2.52)。
  • 心血管死亡:0.6% vs 0.3%,OR 1.95(95%CI 0.19-42.12)。
  • COVID-19进展:38.3% vs 32.3%,OR 1.30(95%CI 0.95-1.80)。
  • 不良事件:需有创机械通气的呼吸衰竭9.6% vs 7.7%;需血管升压药的休克8.4% vs 7.1%;急性心肌梗死7.5% vs 4.6%;新发或加重心衰4.2% vs 4.9%;需血液透析的急性肾衰竭3.3% vs 2.8%。

证据类型、等级与局限

  • 证据类型:随机临床试验(RCT),注册号NCT04364893。
  • 局限:单国(巴西)多中心;仅纳入轻中度COVID-19且入院前在用ACEI/ARB者,不能外推至重度或未用药人群;随访30天。

对床旁实践的改变

  • 对轻中度COVID-19住院且有ACEI/ARB治疗指征者,不因COVID-19诊断而常规停用ACEI/ARB。
  • 停用与否不改变30天出院存活天数、死亡及COVID-19进展等结局。
  • 不适用于入院前未在用ACEI/ARB者、重度COVID-19或非COVID-19人群(原文未纳入)。

指南或共识出处

  • JAMA:Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Tri

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

IMPORTANCE: It is unknown whether angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) have a positive, neutral, or negative effect on clinical outcomes in patients with coronavirus disease 2019 (COVID-19).

OBJECTIVE: To determine whether discontinuation compared with continuation of ACEIs or ARBs changed the number of days alive and out of the hospital through 30 days.

DESIGN, SETTING, AND PARTICIPANTS: A randomized clinical trial of 659 patients hospitalized in Brazil with mild to moderate COVID-19 who were taking ACEIs or ARBs prior to hospitalization (enrolled: April 9-June 26, 2020; final follow-up: July 26, 2020).

INTERVENTIONS: Discontinuation (n = 334) or continuation (n = 325) of ACEIs or ARBs.

MAIN OUTCOMES AND MEASURES: The primary outcome was the number of days alive and out of the hospital through 30 days. Secondary outcomes included death, cardiovascular death, and COVID-19 progression.

RESULTS: Among 659 patients, the median age was 55.1 years (interquartile range [IQR], 46.1-65.0 years), 14.7% were aged 70 years or older, 40.4% were women, and 100% completed the trial. The median time from symptom onset to hospital admission was 6 days (IQR, 4-9 days) and 27.2% of patients had an oxygen saturation of less than 94% of room air at baseline. In terms of clinical severity, 57.1% of patients were considered mild at hospital admission and 42.9% were considered moderate. There was no significant difference in the number of days alive and out of the hospital in patients in the discontinuation group (mean, 21.9 days [SD, 8 days]) vs patients in the continuation group (mean, 22.9 days [SD, 7.1 days]) and the mean ratio was 0.95 (95% CI, 0.90-1.01). There also was no statistically significant difference in death (2.7% for the discontinuation group vs 2.8% for the continuation group; odds ratio [OR], 0.97 [95% CI, 0.38-2.52]), cardiovascular death (0.6% vs 0.3%, respectively; OR, 1.95 [95% CI, 0.19-42.12]), or COVID-19 progression (38.3% vs 32.3%; OR, 1.30 [95% CI, 0.95-1.80]). The most common adverse events were respiratory failure requiring invasive mechanical ventilation (9.6% in the discontinuation group vs 7.7% in the continuation group), shock requiring vasopressors (8.4% vs 7.1%, respectively), acute myocardial infarction (7.5% vs 4.6%), new or worsening heart failure (4.2% vs 4.9%), and acute kidney failure requiring hemodialysis (3.3% vs 2.8%).

CONCLUSIONS AND RELEVANCE: Among patients hospitalized with mild to moderate COVID-19 and who were taking ACEIs or ARBs before hospital admission, there was no significant difference in the mean number of days alive and out of the hospital for those assigned to discontinue vs continue these medications. These findings do not support routinely discontinuing ACEIs or ARBs among patients hospitalized with mild to moderate COVID-19 if there is an indication for treatment.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04364893.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Lopes RD, Macedo AVS, de Barros E Silva PGM, et al. Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial. JAMA. 2021. PMID: 33464336. doi:10.1001/jama.2020.25864

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。